AKT INHIBITOR MK2206, LAPATINIB DITOSYLATE, AND TRASTUZUMAB IN TREATING PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST , GASTRIC, OR GASTROESOPHAGEAL CANCER THAT CANNOT BE REMOVED BY SURGERY: